Jundishapur Journal of Microbiology

Published by: Kowsar

Cloning and Expression of a Secretory form of Truncated ORF2 (aa 112-607) from Hepatitis E Virus in the pVAX1 Vector

Manoochehr Makvandi 1 , 2 , Reza Taherkhani 3 , 4 and Behnam Azizolahi 1 , 2 , *
Authors Information
1 Infectious and Tropical Diseases Research Center, Health Research Institute, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran
2 Department of Medical Virology, School of Medicine, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran
3 Department of Microbiology and Parasitology, School of Medicine, Bushehr University of Medical Sciences, Bushehr, Iran
4 Persian Gulf Tropical Medicine Research Center, Bushehr University of Medical Sciences, Bushehr, Iran
Article information
  • Jundishapur Journal of Microbiology: November 2017, 10 (11); e13543
  • Published Online: September 2, 2017
  • Article Type: Research Article
  • Received: March 8, 2017
  • Revised: May 16, 2017
  • Accepted: June 24, 2017
  • DOI: 10.5812/jjm.13543

To Cite: Makvandi M, Taherkhani R, Azizolahi B. Cloning and Expression of a Secretory form of Truncated ORF2 (aa 112-607) from Hepatitis E Virus in the pVAX1 Vector, Jundishapur J Microbiol. 2017 ; 10(11):e13543. doi: 10.5812/jjm.13543.

Abstract
Copyright © 2017, Jundishapur Journal of Microbiology. This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.
1. Background
2. Objectives
3. Methods
4. Results
5. Discussion
6. Conclusion
Acknowledgements
Footnotes
References
  • 1. Taherkhani R, Farshadpour F. Epidemiology of Hepatitis E in Pregnant Women and Children in Iran: A General Overview. J Clin Transl Hepatol. 2016; 4(3): 269-76[DOI][PubMed]
  • 2. Taherkhani R, Farshadpour F. Epidemiology of hepatitis E virus in Iran. World J Gastroenterol. 2016; 22(22): 5143-53[DOI][PubMed]
  • 3. Srivastava R, Aggarwal R, Jameel S, Puri P, Gupta VK, Ramesh VS, et al. Cellular immune responses in acute hepatitis E virus infection to the viral open reading frame 2 protein. Viral Immunol. 2007; 20(1): 56-65[DOI][PubMed]
  • 4. Jameel S. Molecular biology and pathogenesis of hepatitis E virus. Expert Rev Mol Med. 1999; 1999: 1-16[DOI][PubMed]
  • 5. Farshadpour F, Taherkhani R, Makvandi M. Prevalence of Hepatitis E Virus among Adults in South-West of Iran. Hepat Res Treat. 2015; 2015: 759589[DOI][PubMed]
  • 6. Boccia D, Guthmann JP, Klovstad H, Hamid N, Tatay M, Ciglenecki I, et al. High mortality associated with an outbreak of hepatitis E among displaced persons in Darfur, Sudan. Clin Infect Dis. 2006; 42(12): 1679-84[DOI][PubMed]
  • 7. WHO . Hepatitis E. 2016;
  • 8. Emerson SU. Fields Virology. 2013; : 2242-58
  • 9. WHO . The global prevalence of hepatitis E virus infection and susceptibility: A systematic review. 2010;
  • 10. Taherkhani R, Farshadpour F. A new strategy for development of hepatitis E vaccine: Epitope-based vaccines. Pathog Infect Dis. 2015; 1(1): 1-6
  • 11. Emerson SU, Purcell RH. Recombinant vaccines for hepatitis E. Trends Mol Med. 2001; 7(10): 462-6[DOI][PubMed]
  • 12. Jimenez de Oya N, Escribano-Romero E, Blazquez AB, Lorenzo M, Martin-Acebes MA, Blasco R, et al. Characterization of hepatitis E virus recombinant ORF2 proteins expressed by vaccinia viruses. J Virol. 2012; 86(15): 7880-6[DOI][PubMed]
  • 13. Cao D, Meng XJ. Molecular biology and replication of hepatitis E virus. Emerg Microbes Infect. 2012; 1(8)[DOI][PubMed]
  • 14. Taherkhani R, Makvandi M, Farshadpour F. Development of enzyme-linked immunosorbent assays using 2 truncated ORF2 proteins for detection of IgG antibodies against hepatitis E virus. Ann Lab Med. 2014; 34(2): 118-26[DOI][PubMed]
  • 15. Li TC, Takeda N, Miyamura T, Matsuura Y, Wang JC, Engvall H, et al. Essential elements of the capsid protein for self-assembly into empty virus-like particles of hepatitis E virus. J Virol. 2005; 79(20): 12999-3006[DOI][PubMed]
  • 16. Wang L, Zhuang H. Hepatitis E: an overview and recent advances in vaccine research. World J Gastroenterol. 2004; 10(15): 2157-62[DOI][PubMed]
  • 17. Farshadpour F, Taherkhani R, Makvandi M, Rajabi Memari H, Samarbafzadeh AR. Codon-Optimized Expression and Purification of Truncated ORF2 Protein of Hepatitis E Virus in Escherichia coli. Jundishapur J Microbiol. 2014; 7(7)[DOI][PubMed]
  • 18. Taherkhani R, Farshadpour F, Makvandi M. Design and production of a multiepitope construct derived from hepatitis E virus capsid protein. J Med Virol. 2015; 87(7): 1225-34[DOI][PubMed]
  • 19. Maertens B, Spriestersbach A, von Groll U, Roth U, Kubicek J, Gerrits M, et al. Gene optimization mechanisms: a multi-gene study reveals a high success rate of full-length human proteins expressed in Escherichia coli. Protein Sci. 2010; 19(7): 1312-26[DOI][PubMed]
  • 20. Watts AM, Kennedy RC. DNA vaccination strategies against infectious diseases. Int J Parasitol. 1999; 29(8): 1149-63[DOI][PubMed]
  • 21. Li Z, Howard A, Kelley C, Delogu G, Collins F, Morris S. Immunogenicity of DNA vaccines expressing tuberculosis proteins fused to tissue plasminogen activator signal sequences. Infect Immun. 1999; 67(9): 4780-6[PubMed]
  • 22. Alexander J, Sidney J, Southwood S, Ruppert J, Oseroff C, Maewal A, et al. Development of high potency universal DR-restricted helper epitopes by modification of high affinity DR-blocking peptides. Immunity. 1994; 1(9): 751-61[DOI][PubMed]
  • 23. Farshadpour F, Makvandi M, Taherkhani R. Design, Construction and Cloning of Truncated ORF2 and tPAsp-PADRE-Truncated ORF2 Gene Cassette From Hepatitis E Virus in the pVAX1 Expression Vector. Jundishapur J Microbiol. 2015; 8(12)[DOI][PubMed]
  • 24. Taherkhani R, Farshadpour F, Makvandi M, Samarbafzadeh AR. Cloning of fliC Gene From Salmonella typhimurium in the Expression Vector pVAX1 and Evaluation of its Expression in Eukaryotic Cells. Jundishapur J Microbiol. 2014; 7(11)[DOI][PubMed]
  • 25. Kamar N, Dalton HR, Abravanel F, Izopet J. Hepatitis E virus infection. Clin Microbiol Rev. 2014; 27(1): 116-38[DOI][PubMed]
  • 26. Taherkhani R, Farshadpour F, Makvandi M, Rajabi Memari H, Samarbafzadeh AR, Sharifi N, et al. Cytokine Profiles and Cell Proliferation Responses to Truncated ORF2 Protein in Iranian Patients Recovered from Hepatitis E Infection. J Trop Med. 2015; 2015: 523560[DOI][PubMed]
  • 27. Nguyen HT, Shukla P, Torian U, Faulk K, Emerson SU. Hepatitis E virus genotype 1 infection of swine kidney cells in vitro is inhibited at multiple levels. J Virol. 2014; 88(2): 868-77[DOI][PubMed]
  • 28. Tregoning JS, Kinnear E. Using Plasmids as DNA Vaccines for Infectious Diseases. Microbiol Spectr. 2014; 2(6)[DOI][PubMed]
  • 29. Luo M, Tao P, Li J, Zhou S, Guo D, Pan Z. Immunization with plasmid DNA encoding influenza A virus nucleoprotein fused to a tissue plasminogen activator signal sequence elicits strong immune responses and protection against H5N1 challenge in mice. J Virol Methods. 2008; 154(1-2): 121-7[DOI][PubMed]
  • 30. Le Saout C, Mennechet S, Taylor N, Hernandez J. Memory-like CD8+ and CD4+ T cells cooperate to break peripheral tolerance under lymphopenic conditions. Proc Natl Acad Sci U S A. 2008; 105(49): 19414-9[DOI][PubMed]
  • 31. Tenbusch M, Grunwald T, Niezold T, Storcksdieck Genannt Bonsmann M, Hannaman D, Norley S, et al. Codon-optimization of the hemagglutinin gene from the novel swine origin H1N1 influenza virus has differential effects on CD4(+) T-cell responses and immune effector mechanisms following DNA electroporation in mice. Vaccine. 2010; 28(19): 3273-7[DOI][PubMed]
  • 32. Montgomery DL, Prather KJ. Design of plasmid DNA constructs for vaccines. Methods Mol Med. 2006; 127: 11-22[DOI][PubMed]
  • 33. Rosa DS, Tzelepis F, Cunha MG, Soares IS, Rodrigues MM. The pan HLA DR-binding epitope improves adjuvant-assisted immunization with a recombinant protein containing a malaria vaccine candidate. Immunol Lett. 2004; 92(3): 259-68[DOI][PubMed]
  • 34. Alexander J, del Guercio MF, Frame B, Maewal A, Sette A, Nahm MH, et al. Development of experimental carbohydrate-conjugate vaccines composed of Streptococcus pneumoniae capsular polysaccharides and the universal helper T-lymphocyte epitope (PADRE). Vaccine. 2004; 22(19): 2362-7[DOI][PubMed]
Creative Commons License Except where otherwise noted, this work is licensed under Creative Commons Attribution Non Commercial 4.0 International License .

Search Relations:

Author(s):

Article(s):

Create Citiation Alert
via Google Reader

Readers' Comments